SBPH—6/30/19 cash=$49.2M—2Q19 burn=($15.2M): https://www.globenewswire.com/news-release/2019/07/31/1895158/0/en/Spring-Bank-Pharmaceuticals-Reports-Second-Quarter-2019-Financial-and-Operational-Results-and-Provides-Business-Development-Update.html My view of the HBV program in #msg-148213028 still holds.